Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data from Sexual Health Clinics in Four US Regions
Mycoplasma genitalium (MG) is on the CDC Watch List of Antimicrobial Resistance Threats yet there is no systematic surveillance to monitor change. We initiated surveillance in sexual health clinics in six cities, selecting a quota sample of urogenital specimens tested for gonorrhea and/or chlamydia....
Gespeichert in:
Veröffentlicht in: | Clinical infectious diseases 2023-07 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | Clinical infectious diseases |
container_volume | |
creator | Manhart, Lisa E Leipertz, Gina Soge, Olusegun O Jordan, Stephen J McNeil, Candice Pathela, Preeti Reno, Hilary Wendel, Karen Parker, Anika Geisler, William M Getman, Damon Golden, Matthew R |
description | Mycoplasma genitalium (MG) is on the CDC Watch List of Antimicrobial Resistance Threats yet there is no systematic surveillance to monitor change.
We initiated surveillance in sexual health clinics in six cities, selecting a quota sample of urogenital specimens tested for gonorrhea and/or chlamydia. We abstracted patient data from medical records and detected MG and macrolide resistance mutations (MRM) by nucleic acid amplification testing. We employed Poisson regression to estimate adjusted prevalence ratios (aPR) and 95% confidence intervals (CI), adjusting for sampling criteria (site, birth-sex, symptom status).
From October-December 2020 we tested 1,743 urogenital specimens: 57.0% from males, 46.1% from non-Hispanic Black people, 43.8% from symptomatic patients. MG prevalence was 16.6% (95%CI = 14.9-18.5) (site-specific range = 9.9%-23.5%) and higher in St Louis (aPR = 1.9; 1.27-2.85), Greensboro (aPR = 1.8; 1.18-2.79), and Denver (aPR = 1.7; 1.12-2.44) than Seattle. Prevalence was highest in people |
format | Article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_37402645</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37402645</sourcerecordid><originalsourceid>FETCH-pubmed_primary_374026453</originalsourceid><addsrcrecordid>eNqFjjsLwjAURoMgvv-C3FEHIbWtr9Xn4mLtXK71VqNJWpJG7L9XQWenDw6Hw1djLS_0p6NJOPearG3tjXPPm_GwwZr-NODjSRC22H1fpXkh0SqEC2lRohROgdBQXgniCAb7avvmcTRcQOTMg4SUqFOCFZYImckVRPR0KGFHKMsrLKXQIrWfxCZ35tM40EXk2nZZPUNpqffdDutv1sflblS4k6JzUhih0FTJ753_V3gBgM1Elw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data from Sexual Health Clinics in Four US Regions</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Manhart, Lisa E ; Leipertz, Gina ; Soge, Olusegun O ; Jordan, Stephen J ; McNeil, Candice ; Pathela, Preeti ; Reno, Hilary ; Wendel, Karen ; Parker, Anika ; Geisler, William M ; Getman, Damon ; Golden, Matthew R</creator><creatorcontrib>Manhart, Lisa E ; Leipertz, Gina ; Soge, Olusegun O ; Jordan, Stephen J ; McNeil, Candice ; Pathela, Preeti ; Reno, Hilary ; Wendel, Karen ; Parker, Anika ; Geisler, William M ; Getman, Damon ; Golden, Matthew R ; MyGeniUS study team</creatorcontrib><description>Mycoplasma genitalium (MG) is on the CDC Watch List of Antimicrobial Resistance Threats yet there is no systematic surveillance to monitor change.
We initiated surveillance in sexual health clinics in six cities, selecting a quota sample of urogenital specimens tested for gonorrhea and/or chlamydia. We abstracted patient data from medical records and detected MG and macrolide resistance mutations (MRM) by nucleic acid amplification testing. We employed Poisson regression to estimate adjusted prevalence ratios (aPR) and 95% confidence intervals (CI), adjusting for sampling criteria (site, birth-sex, symptom status).
From October-December 2020 we tested 1,743 urogenital specimens: 57.0% from males, 46.1% from non-Hispanic Black people, 43.8% from symptomatic patients. MG prevalence was 16.6% (95%CI = 14.9-18.5) (site-specific range = 9.9%-23.5%) and higher in St Louis (aPR = 1.9; 1.27-2.85), Greensboro (aPR = 1.8; 1.18-2.79), and Denver (aPR = 1.7; 1.12-2.44) than Seattle. Prevalence was highest in people <18 years (30.4%) and declined 3% per each additional year of age (aPR = 0.97; 0.955-0.982). MG was detected in 26.8%, 21.1%, 11.8% and 15.4% of urethritis, vaginitis, cervicitis, and pelvic inflammatory disease (PID), respectively. It was present in 9% of asymptomatic males and 15.4% of asymptomatic females, and associated with male urethritis (aPR = 1.7; 1.22-2.50) and chlamydia (aPR = 1.7; 1.13-2.53). MRM prevalence was 59.1% (95%CI = 53.1-64.8) (site-specific range = 51.3%-70.6%). MRM were associated with vaginitis (aPR = 1.8; 1.14-2.85), cervicitis (aPR = 3.5; 1.69-7.30), and PID cervicitis (aPR = 1.8; 1.09-3.08).
MG infection is common in people at high risk of STIs; testing symptomatic patients would facilitate appropriate therapy. Macrolide resistance is high and azithromycin should not be used without resistance testing.</description><identifier>EISSN: 1537-6591</identifier><identifier>PMID: 37402645</identifier><language>eng</language><publisher>United States</publisher><ispartof>Clinical infectious diseases, 2023-07</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-4896-7654</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37402645$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Manhart, Lisa E</creatorcontrib><creatorcontrib>Leipertz, Gina</creatorcontrib><creatorcontrib>Soge, Olusegun O</creatorcontrib><creatorcontrib>Jordan, Stephen J</creatorcontrib><creatorcontrib>McNeil, Candice</creatorcontrib><creatorcontrib>Pathela, Preeti</creatorcontrib><creatorcontrib>Reno, Hilary</creatorcontrib><creatorcontrib>Wendel, Karen</creatorcontrib><creatorcontrib>Parker, Anika</creatorcontrib><creatorcontrib>Geisler, William M</creatorcontrib><creatorcontrib>Getman, Damon</creatorcontrib><creatorcontrib>Golden, Matthew R</creatorcontrib><creatorcontrib>MyGeniUS study team</creatorcontrib><title>Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data from Sexual Health Clinics in Four US Regions</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Mycoplasma genitalium (MG) is on the CDC Watch List of Antimicrobial Resistance Threats yet there is no systematic surveillance to monitor change.
We initiated surveillance in sexual health clinics in six cities, selecting a quota sample of urogenital specimens tested for gonorrhea and/or chlamydia. We abstracted patient data from medical records and detected MG and macrolide resistance mutations (MRM) by nucleic acid amplification testing. We employed Poisson regression to estimate adjusted prevalence ratios (aPR) and 95% confidence intervals (CI), adjusting for sampling criteria (site, birth-sex, symptom status).
From October-December 2020 we tested 1,743 urogenital specimens: 57.0% from males, 46.1% from non-Hispanic Black people, 43.8% from symptomatic patients. MG prevalence was 16.6% (95%CI = 14.9-18.5) (site-specific range = 9.9%-23.5%) and higher in St Louis (aPR = 1.9; 1.27-2.85), Greensboro (aPR = 1.8; 1.18-2.79), and Denver (aPR = 1.7; 1.12-2.44) than Seattle. Prevalence was highest in people <18 years (30.4%) and declined 3% per each additional year of age (aPR = 0.97; 0.955-0.982). MG was detected in 26.8%, 21.1%, 11.8% and 15.4% of urethritis, vaginitis, cervicitis, and pelvic inflammatory disease (PID), respectively. It was present in 9% of asymptomatic males and 15.4% of asymptomatic females, and associated with male urethritis (aPR = 1.7; 1.22-2.50) and chlamydia (aPR = 1.7; 1.13-2.53). MRM prevalence was 59.1% (95%CI = 53.1-64.8) (site-specific range = 51.3%-70.6%). MRM were associated with vaginitis (aPR = 1.8; 1.14-2.85), cervicitis (aPR = 3.5; 1.69-7.30), and PID cervicitis (aPR = 1.8; 1.09-3.08).
MG infection is common in people at high risk of STIs; testing symptomatic patients would facilitate appropriate therapy. Macrolide resistance is high and azithromycin should not be used without resistance testing.</description><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFjjsLwjAURoMgvv-C3FEHIbWtr9Xn4mLtXK71VqNJWpJG7L9XQWenDw6Hw1djLS_0p6NJOPearG3tjXPPm_GwwZr-NODjSRC22H1fpXkh0SqEC2lRohROgdBQXgniCAb7avvmcTRcQOTMg4SUqFOCFZYImckVRPR0KGFHKMsrLKXQIrWfxCZ35tM40EXk2nZZPUNpqffdDutv1sflblS4k6JzUhih0FTJ753_V3gBgM1Elw</recordid><startdate>20230704</startdate><enddate>20230704</enddate><creator>Manhart, Lisa E</creator><creator>Leipertz, Gina</creator><creator>Soge, Olusegun O</creator><creator>Jordan, Stephen J</creator><creator>McNeil, Candice</creator><creator>Pathela, Preeti</creator><creator>Reno, Hilary</creator><creator>Wendel, Karen</creator><creator>Parker, Anika</creator><creator>Geisler, William M</creator><creator>Getman, Damon</creator><creator>Golden, Matthew R</creator><scope>NPM</scope><orcidid>https://orcid.org/0000-0002-4896-7654</orcidid></search><sort><creationdate>20230704</creationdate><title>Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data from Sexual Health Clinics in Four US Regions</title><author>Manhart, Lisa E ; Leipertz, Gina ; Soge, Olusegun O ; Jordan, Stephen J ; McNeil, Candice ; Pathela, Preeti ; Reno, Hilary ; Wendel, Karen ; Parker, Anika ; Geisler, William M ; Getman, Damon ; Golden, Matthew R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_374026453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Manhart, Lisa E</creatorcontrib><creatorcontrib>Leipertz, Gina</creatorcontrib><creatorcontrib>Soge, Olusegun O</creatorcontrib><creatorcontrib>Jordan, Stephen J</creatorcontrib><creatorcontrib>McNeil, Candice</creatorcontrib><creatorcontrib>Pathela, Preeti</creatorcontrib><creatorcontrib>Reno, Hilary</creatorcontrib><creatorcontrib>Wendel, Karen</creatorcontrib><creatorcontrib>Parker, Anika</creatorcontrib><creatorcontrib>Geisler, William M</creatorcontrib><creatorcontrib>Getman, Damon</creatorcontrib><creatorcontrib>Golden, Matthew R</creatorcontrib><creatorcontrib>MyGeniUS study team</creatorcontrib><collection>PubMed</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Manhart, Lisa E</au><au>Leipertz, Gina</au><au>Soge, Olusegun O</au><au>Jordan, Stephen J</au><au>McNeil, Candice</au><au>Pathela, Preeti</au><au>Reno, Hilary</au><au>Wendel, Karen</au><au>Parker, Anika</au><au>Geisler, William M</au><au>Getman, Damon</au><au>Golden, Matthew R</au><aucorp>MyGeniUS study team</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data from Sexual Health Clinics in Four US Regions</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2023-07-04</date><risdate>2023</risdate><eissn>1537-6591</eissn><abstract>Mycoplasma genitalium (MG) is on the CDC Watch List of Antimicrobial Resistance Threats yet there is no systematic surveillance to monitor change.
We initiated surveillance in sexual health clinics in six cities, selecting a quota sample of urogenital specimens tested for gonorrhea and/or chlamydia. We abstracted patient data from medical records and detected MG and macrolide resistance mutations (MRM) by nucleic acid amplification testing. We employed Poisson regression to estimate adjusted prevalence ratios (aPR) and 95% confidence intervals (CI), adjusting for sampling criteria (site, birth-sex, symptom status).
From October-December 2020 we tested 1,743 urogenital specimens: 57.0% from males, 46.1% from non-Hispanic Black people, 43.8% from symptomatic patients. MG prevalence was 16.6% (95%CI = 14.9-18.5) (site-specific range = 9.9%-23.5%) and higher in St Louis (aPR = 1.9; 1.27-2.85), Greensboro (aPR = 1.8; 1.18-2.79), and Denver (aPR = 1.7; 1.12-2.44) than Seattle. Prevalence was highest in people <18 years (30.4%) and declined 3% per each additional year of age (aPR = 0.97; 0.955-0.982). MG was detected in 26.8%, 21.1%, 11.8% and 15.4% of urethritis, vaginitis, cervicitis, and pelvic inflammatory disease (PID), respectively. It was present in 9% of asymptomatic males and 15.4% of asymptomatic females, and associated with male urethritis (aPR = 1.7; 1.22-2.50) and chlamydia (aPR = 1.7; 1.13-2.53). MRM prevalence was 59.1% (95%CI = 53.1-64.8) (site-specific range = 51.3%-70.6%). MRM were associated with vaginitis (aPR = 1.8; 1.14-2.85), cervicitis (aPR = 3.5; 1.69-7.30), and PID cervicitis (aPR = 1.8; 1.09-3.08).
MG infection is common in people at high risk of STIs; testing symptomatic patients would facilitate appropriate therapy. Macrolide resistance is high and azithromycin should not be used without resistance testing.</abstract><cop>United States</cop><pmid>37402645</pmid><orcidid>https://orcid.org/0000-0002-4896-7654</orcidid></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1537-6591 |
ispartof | Clinical infectious diseases, 2023-07 |
issn | 1537-6591 |
language | eng |
recordid | cdi_pubmed_primary_37402645 |
source | Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
title | Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data from Sexual Health Clinics in Four US Regions |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T21%3A42%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mycoplasma%20genitalium%20in%20the%20US%20(MyGeniUS):%20Surveillance%20Data%20from%20Sexual%20Health%20Clinics%20in%20Four%20US%20Regions&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Manhart,%20Lisa%20E&rft.aucorp=MyGeniUS%20study%20team&rft.date=2023-07-04&rft.eissn=1537-6591&rft_id=info:doi/&rft_dat=%3Cpubmed%3E37402645%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/37402645&rfr_iscdi=true |